Verbatim): Thrombin cleavage of the thrombin receptors activates an extraordinarily diverse array of physiologic responses. These include platelet aggregation, cellular proliferation/apoptosis, cell-cell adhesion and inflammation, and potentially the invasive and tissue-reorganizing processes involved in cancer. Activation of platelet thrombin receptors is likely to play a major role in the initiation and maintenance of pathological arterial and venous thromboses and the development of atherosclerotic lesions. Four G protein-coupled, protease-activated receptors have been identified: PAR1, PAR2, PAR3, and PAR4. The prototypical protease-activated receptor, PAR1, has been shown to couple to Gq., Gi(betagamma), and G12/13 under a variety of in vitro conditions. The specifics of how PAR1 interacts with the G proteins and the relative importance and temporal ordering of differential G protein activation is still unknown. Far less is known about the identity of the G proteins that couple to the newly discovered PAR3 and PAR4 thrombin receptors. The goals of these studies are: 1) to investigate the mechanistic basis of differential G protein activation by PAR1 under in vivo conditions, 2) to understand the underlying differences between PAR4 and PAR1 G-protein dependent signaling and signal termination, and 3) to expand the repertoire of intracellular proteins that might interact with the class of protease-activated receptors. In the first specific aim we will exploit our newly discovered class of cell-penetrating pepducins. These reagents rapidly penetrate the plasma membrane of intact cells such as platelets and fibroblasts and cause specific activation and/or inhibition of receptor-dependent intracellular signal transduction under in vivo conditions. We have demonstrated that these pepducins exhibit properties that are normally attributable to activated PAR1. These include full platelet aggregation and shape change, stimulation of regulated Ca++ fluxes, activation of phospholipase C, and desensitization of thrombin receptor responses. We anticipate that the use of the pepducins to study intracellular signal transduction will open new avenues of experimental research in cells previously not amenable to molecular techniques. Ultimately, these may prove to be the first therapeutically useful agents that are targeted at receptor-G protein interfaces.
The second aim will explore the mechanistic basis of PAR4 versus PARI-activation of intracellular signaling pathways using a variety of genetic and biochemical techniques. We will expand on recent work done in our lab that demonstrated that PAR1 and PAR4 have distinct kinetics of Ca++ signaling in platelets. In the third aim, we will study coexpressed PAR1 and mammalian G proteins in yeast and will identify novel proteins which specifically interact with PAR1 and PAR4 intracellular domains.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL064701-03
Application #
6625298
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Ganguly, Pankaj
Project Start
2000-12-20
Project End
2005-11-30
Budget Start
2002-12-01
Budget End
2003-11-30
Support Year
3
Fiscal Year
2003
Total Cost
$355,500
Indirect Cost
Name
Tufts University
Department
Type
DUNS #
079532263
City
Boston
State
MA
Country
United States
Zip Code
02111
Foley, C J; Fanjul-Fernández, M; Bohm, A et al. (2014) Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis. Oncogene 33:2264-72
Kaimal, Rajani; Aljumaily, Raid; Tressel, Sarah L et al. (2013) Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res 73:2457-2467
Austin, Karyn M; Covic, Lidija; Kuliopulos, Athan (2013) Matrix metalloproteases and PAR1 activation. Blood 121:431-9
Michael, E S; Kuliopulos, A; Covic, L et al. (2013) Pharmacological inhibition of PAR2 with the pepducin P2pal-18S protects mice against acute experimental biliary pancreatitis. Am J Physiol Gastrointest Liver Physiol 304:G516-26
O'Callaghan, Katie; Lee, Lydia; Nguyen, Nga et al. (2012) Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 119:1717-25
Zhang, Ping; Gruber, Andras; Kasuda, Shogo et al. (2012) Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 126:83-91
O'Callaghan, Katie; Kuliopulos, Athan; Covic, Lidija (2012) Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem 287:12787-96
Foley, Caitlin J; Luo, Chi; O'Callaghan, Katie et al. (2012) Matrix metalloprotease-1a promotes tumorigenesis and metastasis. J Biol Chem 287:24330-8
Tressel, Sarah L; Kaneider, Nicole C; Kasuda, Shogo et al. (2011) A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med 3:370-84
Tressel, Sarah L; Koukos, Georgios; Tchernychev, Boris et al. (2011) Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods Mol Biol 683:259-75

Showing the most recent 10 out of 32 publications